Mechanistic models describing active renal reabsorption and secretion: A simulation-based study

AAPS Journal

Volumn 15, Issue 1, 2013, Pages 278-287

  Felmlee, Melanie A ^a   Dave, Rutwij A ^a   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

kidney transport parameters; models; reabsorption; renal clearance; secretion

Indexed keywords

CHEMICAL COMPOUND;

ARTICLE; BLOOD LEVEL; CALCULATION; COMPARTMENT MODEL; IN VITRO STUDY; KIDNEY CLEARANCE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; MECHANISTIC MODEL; MICHAELIS MENTEN KINETICS; MODEL; NONHUMAN; PHARMACOKINETICS; PREDICTION; SIMULATION; URINARY EXCRETION;

ABSORPTION; ANIMALS; COMPUTER SIMULATION; KIDNEY; MODELS, BIOLOGICAL; PHARMACOKINETICS; PROTEIN BINDING; RATS;

EID: 84871990526     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9437-3     Document Type: Article

References (31)

1. Ganapathy V, Thangaraju M, Gopal E, Martin PM, Itagaki S, Miyauchi S, et al. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9. Epub 2008/05/01.
2. Leibach FH, Ganapathy V. Peptide transporters in the intestine and the kidney. Annu Rev Nutr. 1996;16:99-119. Epub 1996/01/01. (Pubitemid 26286848)
3. Morris ME, Felmlee MA. Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008;10(2):311-21. Epub 2008/06/05.
4. Launay-Vacher V, Izzedine H, Karie S, Hulot JS, Baumelou A, Deray G. Renal tubular drug transporters. Nephron Physiol. 2006;103(3):97-106. Epub 2006/03/24. (Pubitemid 43952619)
5. Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000;58(3):944-58. Epub 2000/09/06.
6. Muller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics. 2011;12(7):1017-37. Epub 2011/07/27.
7. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, et al. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999;291(2):778-84. Epub 1999/10/19. (Pubitemid 29503553)
8. Tamai I, Nakanishi T, Kobayashi D, China K, Kosugi Y, Nezu J, et al. Involvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations. Mol Pharm. 2004;1(1):57-66. Epub 2005/04/19.
9. Hasegawa M, Kusuhara H, Endou H, Sugiyama Y. Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J Pharmacol Exp Ther. 2003;305(3):1087-97. Epub 2003/03/28. (Pubitemid 36617987)
10. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24(7):1227-51. Epub 2007/05/03. (Pubitemid 46876495)
11. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)- organic cation antiporters. Biochem Pharmacol. 2007;74(2):359-71. Epub 2007/05/19. (Pubitemid 46890818)
12. Fagerholm U. Prediction of human pharmacokinetics - renal metabolic and excretion clearance. J Pharm Pharmacol. 2007;59(11):1463-71. Epub 2007/11/03. (Pubitemid 350057448)
13. Paine SW, Menochet K, Denton R, McGinnity DF, Riley RJ. Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab Dispos Biol Fate Chem. 2011;39(6):1008-13. Epub 2011/03/02.
14. Watanabe T, Kusuhara H, Debori Y, Maeda K, Kondo T, Nakayama H, et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos Biol Fate Chem. 2011;39(6):1031-8. Epub 2011/03/09.
15. Watanabe T, Kusuhara H, Sugiyama Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn. 2010;37(6):575-90. Epub 2010/11/11.
16. Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena Jr LR, Wang Y, Levine M. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res. 1997;14(9):1133-9. Epub 1997/11/05. (Pubitemid 27432533)
17. Felmlee MA, Wang Q, Cui D, Roiko SA, Morris ME. Mechanistic toxicokinetic model for gamma-hydroxybutyric acid: inhibition of active renal reabsorption as a potential therapeutic strategy. AAPS J. 2010;12(3):407-16. Epub 2010/05/13.
18. Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Sorgel F. Inhibition of flucloxacillin tubular renal secretion by piperacillin. Br J Clin Pharmacol. 2008;66(5):648-59. Epub 2008/11/27.
19. Russel FG, Wouterse AC, van Ginneken CA. Physiologically based pharmacokinetic model for the renal clearance of phenolsulfonphthalein and the interaction with probenecid and salicyluric acid in the dog. J Pharmacokinet Biopharm. 1987;15(4):349-68. Epub 1987/08/01. (Pubitemid 18045387)
20. Jusko WJ, Levy G. Pharmacokinetic evidence for saturable renal tubular reabsorption of riboflavin. J Pharm Sci. 1970;59(6):765-72. Epub 1970/06/01.
21. Wang X, Wang Q, Morris ME. Pharmacokinetic interaction between the flavonoid luteolin and gamma-hydroxybutyrate in rats: potential involvement of monocarboxylate transporters. AAPS J. 2008;10(1):47-55. Epub 2008/05/01.
22. Komiya I. Urine flow dependence of renal clearance and interrelation of renal reabsorption and physicochemical properties of drugs. Drug Metab Dispos Biol Fate Chem. 1986;14(2):239-45. Epub 1986/03/01. (Pubitemid 16105480)
23. Itagaki S, Shimamoto S, Hirano T, Iseki K, Sugawara M, Nishimura S, et al. Comparison of urinary excretion of phenolsulfonphthalein in an animal model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal Wistar rats: involvement of primary active organic anion transporter. J Pharm Pharm Sci Publ Can Soc Pharm Sci, Soc Can Sci Pharm. 2004;7(2):227-34. Epub 2004/09/16. (Pubitemid 41528896)
24. Wang Q, Darling IM, Morris ME. Transport of gamma-hydroxybutyrate in rat kidney membrane vesicles: role of monocarboxylate transporters. J Pharmacol Exp Ther. 2006;318(2):751-61. Epub 2006/05/19. (Pubitemid 44061250)
25. Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica. 2004;34(2):151-78. Epub 2004/02/27. (Pubitemid 38299716)
26. Brown CD, Sayer R, Windass AS, Haslam IS, De Broe ME, D'Haese PC, et al. Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol. 2008;233(3):428-38.
27. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y. Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006;316(3):1187-94. Epub 2005/11/18. (Pubitemid 43345293)
28. Shima JE, Komori T, Taylor TR, Stryke D, Kawamoto M, Johns SJ, et al. Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. Am J Physiol Renal Physiol. 2010;299:F767-75. Epub 2010/07/30.
29. Chen L, Takizawa M, Chen E, Schlessinger A, Choi JH, Segenthelar J, et al. Genetic polymorphisms in the organic cation transporter 1, OCT1, in Chinese and Japanese populations, exhibit altered function. J Pharmacol Exp Ther. 2010;335:42-50. Epub 2010/07/20.
30. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, et al. Physicochemical determinants of human renal clearance. J Med Chem. 2009;52(15):4844-52. Epub 2009/05/19.
31. Hall S, Rowland M. Relationship between renal clearance, protein binding and urine flow for digitoxin, a compound of low clearance in the isolated perfused rat kidney. J Pharmacol Exp Ther. 1984;228(1):174-9. Epub 1984/01/01. (Pubitemid 14223398)